gedeon richter press presentation 2013q2 final2 · 2014. 5. 9. · summary – 2013 h1 13h1 2013 h1...
TRANSCRIPT
Richter Group13H1
Richter Group
Interim Report, 13H1 1 August 2013
Summary – 2013 H113H1
Summary 2013 H1
Consolidated sales: + 6.9% (EUR), + 7.1% (HUF)− good growth in China in EU15 countries and in Ukrainegood growth in China, in EU15 countries and in Ukraine− price erosion
Profit for the period*: +1.3% (EUR), +1.6% (HUF)+ increasing gross profit− higher level of S&M expensesg p
*Net income attributable to owners of the parent
22
Consolidated financial highlights13H1
Consolidated financial highlights
HUF Change EUR Changeg g
Total revenues 177.9 bn 7.1% 601.1 m 6.9%
Profit from operations 30.0 bn 4.2% 101.3 m 3.9%
Profit for the period* 28 6 bn 1 6% 96 5 m 1 3%Profit for the period 28.6 bn 1.6% 96.5 m 1.3%
EPS (diluted) 1,532 1.6% 5.18 1.3%
*Net income attributable to owners of the parent
3
Geographical composition of Group sales13H1
Geographical composition of Group sales
10%
7%
Hungary
RussiaPoland
10%6%
Hungary
Russia Poland7%
12%
31%
Romania2012 H1
2013 H1
6%29%
12% Romania
8 %
5 %
10%
7%
%
EU9Ukraine
H1 H1
6 % 7%
8 % 10%3%
EU9
Oth CIS
Ukraine
1%4% EU15USA
Other CIS 5%
RoW
4% 5%
China
3% EU15USA
Other CIS
RoW
1%
China
Total: HUF 166.0bnEUR 562.4m
Total: HUF 177.9bnEUR 601.1m
7.1% HUF6.9% EUR+
44
P&L13H1
P&L
HUFmH1 2013
Change %
EURmH1 2013
Change %
as % of total revenues
Total revenues 177,877 7.1 601.1 6.9
Gross profit 113,695 10.0 384.2 9.8 63.9
S&M expenses (55,468) 19.4 (187.4) 19.1 31.2
A&G expenses (9,618) -11.3 (32.5) -11.4 5.4
R&D expenses (20,769) 3.7 (70.2) 3.5 11.7
Other income and other expenses 2,120 -23.1 7.2 -23.4 1.2
Profit from operations 29,960 4.2 101.3 3.9 16.8
Net financial income 451 -39.3 1.5 -40.0 0.3
Profit for the period* 28,557 1.6 96.5 1.3 16.1
*Profit attributable to owners of the parent
5
Increasing gross profit and gross margin13H1
Increasing gross profit and gross margin
+ higher than average increase of turnover in China, in Ukraine, in EU15 countries and in other CIS 63.9%
HUF
60%
62%
64%
200000
250000region
+ increasing share of
62.2%HUFm
52%
54%
56%
58%
50000
100000
150000g
own-developed products
decline in the high margin US48%
50%
0
50000
2006 2007 2008 2009 2010 2011 2012 12H1 13H1
- decline in the high margin US business
Gross profit Gross margin
6
Slight decline of operating margin13H1
Slight decline of operating margin
Sales and marketing expensesSales and marketing expenses− expanding sales network in
Western Europe− Esmya® launches HUFm
15,0%
20,0%
25,0%
40000
50000
60000
70000y
− S&M activities in China
Research and development 17.3% 16.8%
5,0%
10,0%
15,0%
10000
20000
30000
40000p
expenses− Forest, PregLem, biosimilar
research
0,0%0
10000
2006 2007 2008 2009 2010 2011 2012 12H1* 13H1
Profit from operation Operating margin
Amortisation− Esmya® + Grünenthal OCs
*Restated due to reclassification of innovation fee.
7
Pharmaceutical sales*13H1
Pharmaceutical sales
Key drivers of growth:
China, EU15 countries and Ukraine
Female healthcare
Successful product launches
*89% of turnover originates from outside of Hungary
8
g g y
8
Hungary13H1
Hungary
Turnover *Sales increase: 3.8% in HUF
HUFbn
30
40Successful product launches− Esmya®
10
20
02007 2008 2009 2010 2011 2012 12H1 13H1
*Turnover of the pharmaceutical segment
9
EU – composition of sales*13H1
EU composition of sales
Traditional EU member states 38%states− strengthening our position
in key Western-European markets
62%
markets− own gynaecological sales
and marketing network
Poland, Romania, EU9− well established in the region for
decades− own specialized sales network* Turnover of the pharmaceutical segment p
10
EU1513H1
EU15
120
Turnover*
10.1% (EUR) sales increase
R tl t bli h d S&MEURm
80
100
120Recently established S&M network
20
40
60
Female healthcare products: Richter OC portfolio, acquired OCs Esmya®
02007 2008 2009 2010 2011 2012 12H1 13H1
OCs, Esmya®
*Turnover of the pharmaceutical segment
11
Poland, Romania, EU913H1
Poland, Romania, EU9
M d t d li f t
Turnover*
Moderate decline of turnover
Unfavourable macroeconomic EURm
100
150
200environment
Poland:
0
50
100Poland: – sales decrease of 5.9% in PLN− expiry of Avonex licensing
agreement 2007 2008 2009 2010 2011 2012 12H1 13H1
Poland Romania EU9
agreement− adjusted sales with Avonex:
+5.7% in PLN
Romania:– flat sales levels
*Turnover of the pharmaceutical segment
– delays in payment12
CIS13H1
CIS
Turnover*
Slight sales increase (+3.9% EUR)
EURm
300
400
500Dynamic growth: Ukraine
100
200
300
Russia: expiry of Suprax licencing agreement
02007 2008 2009 2010 2011 2012 12H1 13H1
Russia Ukraine Other CIS
*Turnover of the pharmaceutical segment
13
Russia13H1
Russia
Sales increase (+2 4% RUB;
Turnover*
Sales increase (+2.4% RUB; +0.9% EUR)
EURm
300
400Expiry of Suprax licensing agreement(revenue loss: RUB 0.5 bn/
100
200(EUR 11.5 m)
Adjusted sales with Suprax0
2007 2008 2009 2010 2011 2012 12H1 13H1
Adjusted sales with Suprax(+9.7%RUB; +8.0%EUR)
Effective marketing activity
Increase of manufacturing and
*Turnover of the pharmaceutical segment
Increase of manufacturing and warehousing capacities
14
Ukraine, Other republics13H1
Ukraine, Other republics
Turnover*Ukraine
23 6% increase (USD)USDm
150
200− 23.6% increase (USD)− effective marketing activity
Oth bli50
100Other republics− 5.2% increase (USD)
02007 2008 2009 2010 2011 2012 12H1 13H1
Ukraine Kazakhstan Other CIS
*Turnover of the pharmaceutical segment
15
USA13H1
USA
Turnover*Revenue loss (-23.0% USD)
USDm
160
200
Significant proportion of gynaecology – 90%
40
80
120gy gy
Declining female healthcare l
02007 2008 2009 2010 2011 2012 12H1 13H1
sales
*Turnover of the pharmaceutical segment
16
China13H1
China
Dynamically expanding pharmaceutical market
From 2013 JV operates with Richter majority stake
Sales network: 200 medical representatives
S l i 2013 H1 EUR 24 9 illiSales in 2013 H1: EUR 24.9 million
Preshipments: EUR 9 5 millionPreshipments: EUR 9.5 million
17
Pharmaceutical sales by therapeutic areas13H1
Pharmaceutical sales by therapeutic areas
OtherCentral nervous
system
13%
6%
17%Muscle
relaxants
28%4%Gastrointestinal Cardiovascular2013 H1
32%Gynaecology
Total: EUR 525.9m
18
Female healthcare sales by region13H1
Female healthcare sales by region
806% CEE
Hungary
CIS
HUFbn
20
40
6013%31%
Ex-Grünenthal
0
20
28%
10%4%
8%
EU15
portfolio
China
Gynaecological sales Non‐gynaecological sales
USARoW
EU15
Total: HUF 49.0bnEUR 165.5m
1919
Sales network13H1
Sales network
1800
staff
1200
1400
1600
1800
600
800
1000
0
200
400
2005 2006 2007 2008 2009 2010 2011 2012 12H1 13H12005 2006 2007 2008 2009 2010 2011 2012 12H1 13H1
CIS CEE Hungary EU15 China
20
Wholesale and retail13H1
Wholesale and retail
W&R sales contributions is 15% of total sales
71% of the W&R turnover originates in Romania
2121
Ownership structure13H1
Ownership structure
30 June 2013
Domestic investors
International investors
65.98%
25 24%
8.78%
Hungarian State Holding Company
25.24%
2222
13H1
Thank you for your attention!y y
23
Appendix13H1
Appendix
Exchange rates
24
Evolution of currency exchange rates13H1
Evolution of currency exchange rates
HUF
300
330
270
300
210
240
EUR/HUF
USD/HUF
150
180
25
Exchange rates13H1
Exchange rates
At i d dAt period end30.06.2013 31.03.2013 31.12.2012 30.09.2012 30.06.2012
EUR/HUF 295 16 304 30 291 29 283 71 288 22EUR/HUF 295.16 304.30 291.29 283.71 288.22
USD/HUF 226.18 237.36 220.93 219.17 229.13
RUB/HUF 6.91 7.65 7.26 7.09 6.96
Average2013 H1 2013 Q1 2012 M12 2012 M9 2012 H1
EUR/HUF 295.9 296.1 289.1 291.3 295.2
USD/HUF 225.1 224.0 225.0 227.3 227.7
RUB/HUF 7.3 7.4 7.2 7.3 7.4
26